主页 > 医学信息 >
【medical-news】阿尔茨海默病的发病机制不是β淀粉
The finding, published in the journal Science, may help explain why people with Alzheimer's accumulate sticky clumps of a protein called amyloid beta, and it may help drug companies hone in on potential treatments.
"In people who have Alzheimer's disease, we know there are very large amounts of amyloid beta in the brain," said Dr. Randall Bateman of Washington University in St. Louis, who worked on the study.
Bateman said in a telephone interview people with Alzheimer's disease have between 100 and 1,000 times the normal amount of amyloid in their brains.
"The question was, 'How did all of that get there?'"
He said the brain normally makes amyloid beta, so the team compared the rate at which the brain produced and got rid of amyloid beta in 12 people with Alzheimer's disease and 12 healthy people.
They found no difference in the levels of amyloid produced by either group, but they found a 30 percent reduction in the rate at which Alzheimer patients cleared the protein from the brain.
"I think it tells us that is the major mechanism that is awry in Alzheimer's disease," Bateman said. "Further, it tells us about how fast things happen.'
The team estimates that a 30 percent decrease in the ability to clear amyloid in the brain would mean the disease starts about 10 years before people start to show signs of mental impairment.
"That may be an ideal time to try to correct that imbalance by clearing that amyloid beta and hopefully delaying or preventing Alzheimer's disease," he said.
Alzheimer's is the most common form of dementia, a fatal brain-wasting disease that affects memory, thinking, behavior and the ability to handle daily activities.
Many researchers think early efforts to make drugs that clear amyloid from the brain have failed because they were tried on people after the disease had progressed too far to do any good.
Current Alzheimer's drugs such as Eisai Co (4523.T) and Pfizer Inc's (PFE.N) Aricept or donezepil, and Forest Laboratories' (FRX.N) Namenda or memantine, treat symptoms, but so far nothing has been shown to improve memory and thinking in people with the disease.
Diagnostic and drug companies are now looking for ways to diagnose the disease earlier. Last week, General Electric Co's (GE.N) GE Healthcare and Johnson & Johnson (JNJ.N) announced a research collaboration to find biological signals to detect Alzheimer's disease at an earlier stage [ID:nN01165799].
Alzheimer's affects 26 million people in the world -- most of them elderly -- and costs $604 billion to treat. (Editing by Jackie Frank)
请把题目翻译一下！ 认领，48小时未交译文，请其他战友自由认领。 Instead of producing too much of a amyloid beta protein, people with Alzheimer's disease
阿尔茨海默病的发病机制关键不是β淀粉样蛋白的产生太多而是清除障碍
CHICAGO, Dec 9 (Reuters) - Instead of producing too much of a protein, people with Alzheimer's disease appear to have trouble getting rid of it, U.S. researchers said on Thursday.
1 2010年12月9日，星期四，路透社芝加哥报道了一组美国的研究人员的试验研究结果—阿尔茨海默病的发病机制关键不是β淀粉样蛋白的产生太多而是清除障碍所致。
The finding, published in the journal Science, may help explain why people with Alzheimer's accumulate sticky clumps of a protein called amyloid beta, and it may help drug companies hone in on potential treatments.
2 发表在《科学》杂志上的这项试验研究发现可能有助于解释为什么阿尔茨海默病患者脑部积聚了大量的难于处理的被称为β淀粉样斑块，同时，也有助于药物研究与开发公司开发出有效的治疗阿尔茨海默病药物。
"In people who have Alzheimer's disease, we know there are very large amounts of amyloid beta in the brain," said Dr. Randall Bateman of Washington University in St. Louis, who worked on the study.
3 参与此项试验研究的华盛顿大学圣路易斯分校兰德尔?贝特曼博士说：“众所周知，阿尔茨海默病患者脑部积聚了大量的β淀粉样肽。”
Bateman said in a telephone interview people with Alzheimer's disease have between 100 and 1,000 times the normal amount of amyloid in their brains.
4 贝特曼博士在电话访谈中说，阿尔茨海默病患者脑部的β淀粉样肽为正常人的100倍～1000倍。
"The question was, 'How did all of that get there?'"
5 “问题是所有这些β淀粉样肽是‘怎么到达那里的呢？’”
He said the brain normally makes amyloid beta, so the team compared the rate at which the brain produced and got rid of amyloid beta in 12 people with Alzheimer's disease and 12 healthy people.
6 贝特曼博士说，因为大脑在生理情况下能够制造β淀粉样蛋白，所以，该研究小组比较了12名健康受试者和12名阿尔茨海默病患者脑部的β淀粉样蛋白的产生和清除速率。
阅读本文的人还阅读：
科技新动态：牙齿再生不
作者:admin@医学,生命科学 2011-01-12 23:25
医学,生命科学网